News
BLU
14.74
0.00%
0.00
GRP Limited Secures Second Refund Instalment
TipRanks · 04/19 09:47
From AI to Obesity Drugs - Global Pharma Has $700B For M&A and Investments: Goldman Sachs
Benzinga · 07/07/2023 17:18
GSK completes $2B acquisition of Bellus Health
Seeking Alpha · 06/28/2023 16:51
Bellus Health Inc: Report of foreign issuer
Press release · 06/28/2023 16:12
Press Release: Stock-exchange announcement - For media and investors only - GSK completes acquisition of BELLUS Health
Dow Jones · 06/28/2023 14:57
*Stock-exchange Announcement - For Media And Investors Only - GSK Completes Acquisition Of BELLUS Health >GSK.LN BLU.T
Dow Jones · 06/28/2023 14:57
*GSK PLC Has Bought Bellus For $2.0B
Dow Jones · 06/28/2023 14:45
BTIG Reaffirms Their Hold Rating on BELLUS Health (BLU)
TipRanks · 06/17/2023 14:25
Bellus Health Inc: Report of foreign issuer
Press release · 06/16/2023 21:26
Press Release: BELLUS Health Inc. Announces Voting Results from Special Meeting of Shareholders
Dow Jones · 06/16/2023 17:50
Catalyst watch: AI talk from Salesforce and AMD, Shell event and Oracle earnings
Seeking Alpha · 06/09/2023 19:00
Bellus Health Inc: Report of foreign issuer
Press release · 06/06/2023 21:19
Bellus Health Inc: Report of foreign issuer
Press release · 06/02/2023 21:46
Bellus Health Inc: Report of foreign issuer
Press release · 05/19/2023 17:28
*BELLUS Health: Special Meeting to Be Held on June 16 >BLU
Dow Jones · 05/16/2023 21:02
Press Release: BELLUS Health Inc. Calls Special Shareholders' Meeting in Connection with GSK Acquisition
Dow Jones · 05/16/2023 21:01
Bellus Health Inc: Report of foreign issuer
Press release · 05/16/2023 17:05
RBC Capital Sticks to Their Hold Rating for BELLUS Health (BLU)
TipRanks · 05/15/2023 20:25
RBC Capital Reiterates Sector Perform on BELLUS Health, Maintains $14.75 Price Target
Benzinga · 05/15/2023 12:43
BELLUS Health: Q1 Earnings Insights
Benzinga · 05/12/2023 21:05
More
Webull provides a variety of real-time BLU stock news. You can receive the latest news about Bellus Health Inc through multiple platforms. This information may help you make smarter investment decisions.
About BLU
BELLUS Health Inc. is a clinical-stage biopharmaceutical company developing therapeutics for the treatment of refractory chronic cough (RCC) and other cough hypersensitivity indications. The Company's lead product candidate, BLU-5937, which is a selective, small molecule antagonist of the P2X3 receptor, as an oral therapy to reduce cough frequency in RCC patients. The Company has completed the BLUEPRINT clinical trial, a Phase II trial evaluating BLU-5937 in patients with chronic pruritus associated with AD. The Company is focused on initiating Phase III program. The Company is exploring the use of BLU-5937 in other patient populations experiencing cough hypersensitivity as well as other P2X3-related hypersensitization conditions.